首页> 外文OA文献 >p53-Inducible Ribonucleotide Reductase (p53R2/RRM2B) Is a DNA Hypomethylation–Independent Decitabine Gene Target That Correlates with Clinical Response in Myelodysplastic Syndrome/Acute Myelogenous Leukemia

【2h】

p53-Inducible Ribonucleotide Reductase (p53R2/RRM2B) Is a DNA Hypomethylation–Independent Decitabine Gene Target That Correlates with Clinical Response in Myelodysplastic Syndrome/Acute Myelogenous Leukemia

机译：P53-诱导核糖核苷酸还原酶（P53R2 / RRM2B）是DNA低甲基化无依赖的二章基因靶标，与髓细胞增强综合征/急性髓性白血病中的临床反应相关

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Petra A. Link; Maria R. Baer; Smitha R. James; David A. Jones; Adam R. Karpf;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. [J] . Link PA, Baer MR, James SR, Cancer research: The official organ of the American Association for Cancer Research, Inc . 2008,第22期

机译：p53诱导型核糖核苷酸还原酶（p53R2 / RRM2B）是一种独立于DNA低甲基化的地西他滨基因靶标，与骨髓增生异常综合症/急性骨髓性白血病的临床反应相关。
2. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. [J] . Link PA, Baer MR, James SR, Cancer research: The official organ of the American Association for Cancer Research, Inc . 2008,第22期

机译：p53诱导型核糖核苷酸还原酶（p53R2 / RRM2B）是一种独立于DNA低甲基化的地西他滨基因靶标，与骨髓增生异常综合症/急性骨髓性白血病的临床反应相关。
3. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. [J] . Link PA, Baer MR, James SR, Cancer research: The official organ of the American Association for Cancer Research, Inc . 2008,第22期

机译：p53诱导型核糖核苷酸还原酶（p53R2 / RRM2B）是一种独立于DNA低甲基化的地西他滨基因靶标，与骨髓增生异常综合症/急性骨髓性白血病的临床反应相关。
4. Azanudeoside DNA Methyltransferase Inhibitor Drugs: Update on Clinical Applications in Myelodysplastic Syndromes and Acute Myeloid Leukemia [C] . Michael Lubbert, Michael Daskalakis, Philipp N. Ser, Weissenburg Symposium Biriciana . 2016

机译：硫代稳产苷DNA甲基转移酶抑制剂药物：更新骨髓增生综合征和急性髓性白血病的临床应用
5. Chromosomal mapping of genes encoding human Pur-alpha and Pur-beta: Independent and simultaneous deletions in myelodysplastic syndromes and acute myelogenous leukemia. [D] . Lezon-Geyda, Kimberly Ann. 2001

机译：编码人Pur-alpha和Pur-beta的基因的染色体作图：骨髓增生异常综合症和急性骨髓性白血病的独立和同时缺失。
6. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in MDS/AML [O] . Petra A. Link, Maria R. Baer, Smitha R. James, -1

机译：p53诱导型核糖核苷酸还原酶（p53R2 / RRM2B）是一种DNA低甲基化独立的地西他滨基因靶标与MDS / AML中的临床反应相关
7. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome [O] . Pusic Iskra, Choi Jaebok, Fiala Mark A., 2015

机译：同种异体干细胞移植后地卡他滨维持治疗急性粒细胞白血病和骨髓增生异常综合症

p53-Inducible Ribonucleotide Reductase (p53R2/RRM2B) Is a DNA Hypomethylation–Independent Decitabine Gene Target That Correlates with Clinical Response in Myelodysplastic Syndrome/Acute Myelogenous Leukemia

著录项

相似文献

相关主题

期刊订阅